AD pathology‐independent effects of astrocyte‐ or microglia‐specific replacement of APOE4 with APOE2

作者：Georgia L. Nolt, Steven M. MacLean, Lesley R. Golden, Isaiah O. Stephens, Gabriela Hernandez, Dahlia Siano, E.M. Woodward, Joshua Moses, Josh M. Morganti, Lance A. Johnson · 发表于：Alzheimer s & Dementia · 年份：2024 · DOI：10.1002/alz.091247 · 研究领域：Alzheimer's disease research and treatments、Neuroinflammation and Neurodegeneration Mechanisms、Neurogenesis and neuroplasticity mechanisms

BACKGROUND: Compared with the E3 allele of Apolipoprotein E (APOE), E4 increases late-onset Alzheimer's Disease (AD) risk up to 15-fold, while the E2 allele substantially decreases risk. In the CNS, ApoE is predominantly synthesized by astrocytes and microglia, making these two cell types promising targets for ApoE-directed therapeutic approaches. Our lab has generated an inducible "switch" mouse model (APOE4s2) in which we can conditionally replace E4 with the protective E2 in a cell-specific manner. To elucidate potential mechanisms by which astrocytes and microglia expressing E2 or E4may modulate AD risk, we characterized the immuno-metabolic response of astrocyte- and microglia-specific "switch" mice to a variety of CNS-related challenges. METHOD: Aged APOE4s2 mice were administered tamoxifen to induce an in vivo transition from expression of E4 to E2 selectively in astrocytes (Aldh1l1-CreERT2) or microglia (Tmem119-CreERT2). A separate cohort of APOE4s2 mice received LPS to induce an inflammatory response 24 hours prior to tissue collection. Immunohistochemical analysis of gliosis (GFAP, IBA1), cytokine measurements, and targeted metabolomics and lipidomics were performed on brain tissue from these groups. Additionally, a cohort of 6-week-old microglia-APOE4s2 mice were administered lysophosphatidylcholine (LPC) via intracranial injections to promote demyelination. Mice were sacrificed 10 days post-LPC injection, and myelin content and glial reactivity were quantified vi...